Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial

We have studied a three drug combination with bortezomib, cyclophosphamide and dexamethasone (CyBorD) on a 28 day cycle in the treatment of newly diagnosed multiple myeloma patients to assess response and toxicity. The primary endpoint of response was evaluated after four cycles. Thirty-three newly...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Reeder, Craig B., Reece, Donna E., Kukreti, Vishal, Chen, Christine, Trudel, Suzanne, Hentz, Joseph, Noble, Brie, Pirooz, Nicholas A., Spong, Jacy E., Piza, Jesus G., Zepeda, Victor H. Jimenez, Mikhael, Joseph R., Leis, Jose F., Bergsagel, P. Leif, Fonseca, Rafael, Stewart, A. Keith
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2711213/
https://ncbi.nlm.nih.gov/pubmed/19225538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2009.26
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares